Earnings Data
Report Date
Aug 17, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive financial and operational picture driven by a $25 million milestone that produced Q1 profitability and strengthened the balance sheet to $51 million in cash. Management reaffirmed 2026 guidance and highlighted commercial and regulatory progress for Elfabrio and continued advancement of the PRX-115 program. Offsetting risks include a notable decline in product sales quarter-over-quarter (-26% in selling goods), increased R&D spend (+54%), and timing/visibility uncertainties tied to Chiesi reimbursement rollouts and trial enrollment pace. Overall, the positives (milestone, cash position, profitability, reaffirmed guidance, and clinical progress) materially outweigh the near-term revenue timing and expense increases.Company Guidance
Milestone Payment and Cash Position
Received a $25.0 million milestone from Chiesi following European Commission approval of Elfabrio every-4-weeks dosing; ended Q1 2026 with $51.0 million in cash, cash equivalents and short-term bank deposits, and no outstanding debt or warrants, providing substantial financial flexibility.
Reaffirmed 2026 Revenue Guidance
Reaffirmed full-year 2026 guidance of approximately $78 million to $83 million total revenue (inclusive of the $25 million milestone). Within that outlook, company expects Elfabrio revenues (excluding milestones) of ~$33 million to $35 million and Elelyso revenues of ~$20 million to $23 million.
Quarterly Profitability Driven by Milestone
Reported Q1 2026 net income of $18.3 million ($0.23 per share; $0.22 fully diluted) versus a net loss of $3.6 million ($0.05 per share) in Q1 2025 — a positive swing of $21.9 million year-over-year, largely attributable to the $25 million milestone.
Commercial Momentum for Elfabrio
European EC approval of Elfabrio every-4-weeks regimen is expected to reduce treatment burden and strengthen competitive position; company projects Elfabrio could capture 15%–20% of the global Fabry market (global Fabry market projected to approach ~$3.2 billion by 2031).
Progress on Clinical Pipeline — PRX-115
PRX-115 Phase II RELEASE study is actively enrolling with top-line results anticipated in the second half of 2027; company increased R&D investment to support study initiation and sees PRX-115 as a top clinical priority.
Lower Cost of Revenues Supporting Margins
Cost of revenues decreased to $4.1 million in Q1 2026 from $8.2 million in Q1 2025 (approximately a 50% reduction), reflecting lower volumes to certain partners and contributing to improved gross margin in the quarter.
DE:PBDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:PBDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | €1.62 | €1.63 | +0.25% |
Mar 18, 2026 | €2.38 | €1.92 | -19.33% |
Nov 13, 2025 | €1.82 | €1.65 | -9.29% |
Aug 14, 2025 | €1.37 | €1.28 | -6.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Protalix Biotherapeutics (DE:PBDA) report earnings?
Protalix Biotherapeutics (DE:PBDA) is schdueled to report earning on Aug 17, 2026, TBA (Confirmed).
What is Protalix Biotherapeutics (DE:PBDA) earnings time?
Protalix Biotherapeutics (DE:PBDA) earnings time is at Aug 17, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Protalix Biotherapeutics stock?
The P/E ratio of Protalix is N/A.
What is DE:PBDA EPS forecast?
DE:PBDA EPS forecast for the fiscal quarter 2026 (Q2) is >-0.01.